Showing results (1-10 of 70) with videos related to
Sort By:
Pageof 7
Nederlands Tijdschrift Voor Geneeskunde|March 23, 2011
[Obesity-related hypertension]Jannick A N Dorresteijn, Frank L J Visseren, A H van den Meiracker, et al.Current Opinion in Lipidology|September 21, 2018
The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementationNicole E M Jaspers, Paul M Ridker, Jannick A N Dorresteijn, et al.Journal of Clinical Epidemiology|October 8, 2017
An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart diseaseAnoukh van Giessen, G Ardine de Wit, Karel G M Moons, et al.Diabetes Care|August 17, 2019
Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD TrialTamar I de Vries, Jannick A N Dorresteijn, Yolanda van der Graaf, et al.Journal of the American Heart Association|February 20, 2017
Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease PatientsManon C Stam-Slob, Yolanda van der Graaf, Jacoba P Greving, et al.Diagnostic and Prognostic Research|April 23, 2020
Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?Gijs F N Berkelmans, Jacoba P Greving, Yolanda van der Graaf, et al.Nederlands Tijdschrift Voor Geneeskunde|October 26, 2018
[Cholesterol-lowering drugs in the elderly. When to initiate, maintain or discontinue therapy?]Emma E F Kleipool, Jannick A N Dorresteijn, Frank L J Visseren, et al.Clinical Hypertension|November 1, 2017
Identifying treatment response to antihypertensives in patients with obesity-related hypertensionIlse M Schrover, Jannick A N Dorresteijn, Jodine E Smits, et al.European Journal of Preventive Cardiology|June 20, 2023
The relevance of competing risk adjustment in cardiovascular risk prediction models for clinical practiceSteven H J Hageman, Jannick A N Dorresteijn, Lisa Pennells, et al.Open Heart|April 23, 2022
Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatmentMari Nordbø Gynnild, Steven H J Hageman, Olav Spigset, et al.Pageof 7